Security key
55234L105
Lyra Therapeutics, Inc. - Common Stock, $0.001 par value (LYRA)
CUSIP: 55234L105
Q1 2023 13F Holders as of 31 Mar 2023
- Security type / class
- Equity / Common Stock, $0.001 par value
- Total 13F shares
- 18,925,568
- Total 13F value
- $38,103,347
- Share change
- -147,892
- Put/Call ratio
- 12%
- SEC-reported price per share
- $2.01
- Number of holders
- 30
- Value change
- -$358,723
- Number of buys
- 7
- Number of sells
- 10
- Shares outstanding
- 1,644,695
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2023
Institutions
30
Top holders
10
LYRA full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
Lyra Therapeutics, Inc. SEC filings
Lyra Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 55234L105
Recent filing periods:
Ownership snapshot
Top reported holders of LYRA - Lyra Therapeutics, Inc. - Common Stock, $0.001 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
PERCEPTIVE ADVISORS LLC
Disclosed value leader
PERCEPTIVE ADVISORS LLC
Comparable rows
15/15
Latest evidence
31 Dec 2022
13F
Lead comparable stake: 556%
Showing 1-6 of 15 holder rows.
Quick read
PERCEPTIVE ADVISORS LLC leads the comparable SEC ownership view at 556%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens PERCEPTIVE ADVISORS LLC's linked filing trail.
Comparable ownership
Top 5
PERCEPTIVE ADVISORS LLC
556%
Nantahala Capital Management, LLC
135%
PURA VIDA INVESTMENTS, LLC
131%
Samsara BioCapital, LLC
108%
Venrock Adviser, LLC
56%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC |
13F
Company
|
556%
|
$28,720,732
9,146,730 shares
|
— | 31 Dec 2022 |
| Nantahala Capital Management, LLC |
13F
Company
|
135%
|
$6,973,406
2,220,830 shares
|
— | 31 Dec 2022 |
| PURA VIDA INVESTMENTS, LLC |
13F
Company
|
131%
|
$6,773,916
2,157,298 shares
|
— | 31 Dec 2022 |
| Samsara BioCapital, LLC |
13F
Company
|
108%
|
$5,580,568
1,777,251 shares
|
— | 31 Dec 2022 |
| Venrock Adviser, LLC |
13F
Company
|
56%
|
$2,901,894
924,170 shares
|
— | 31 Dec 2022 |
| VANGUARD GROUP INC |
13F
Company
|
48%
|
$2,483,539
790,936 shares
|
— | 31 Dec 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2023
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
30
Shares
18,925,568
Rows available
30
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2023 vs Q3 2025 Across Filers
Q3 2025 holders
0
Q1 2023 holders
30
Holder diff
30
| Investor | Q3 2025 Shares | Q1 2023 Shares | Share Diff | Share Chg % | Q3 2025 value | Q1 2023 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend